27960292|t|Ankaflavin and Monascin Induce Apoptosis in Activated Hepatic Stellate Cells through Suppression of the Akt / NF-κB / p38 Signaling Pathway
27960292|a|The increased proliferation of activated hepatic stellate cells (HSCs) is associated with hepatic fibrosis and excessive extracellular matrix (ECM)- protein production. We examined the inhibitory effects of the Monascus purpureus -fermented metabolites, ankaflavin and monascin (15 and 30 μM), on the Akt / nuclear factor (NF)-κB and p38 mitogen-activated protein kinase (MAPK) signaling pathways in HSC-T6 (activated hepatic stellate cell line). Ankaflavin and monascin (30 μM) induced apoptosis and significantly inhibited cell growth (cell viabilities: 80.2 ± 5.43% and 62.8 ± 8.20%, respectively, versus control cells; P < 0.05). Apoptosis and G1 phase arrest (G1 phase percentages: 76.1 ± 2.85% and 79.9 ± 1.80%, respectively, versus control cells 65.9 ± 4.94%; P < 0.05) correlated with increased p53 and p21 levels and caspase 3 activity and decreased cyclin D1 and Bcl-2-family protein levels (P < 0.05, all cases). The apoptotic effects of ankaflavin and monascin were HSC-T6 - specific, suggesting their potential in treating liver fibrosis.
27960292	0	10	Ankaflavin	T109,T123	C1568221
27960292	15	23	Monascin	T109	C1871155
27960292	24	30	Induce	T169	C0205263
27960292	31	40	Apoptosis	T043	C0162638
27960292	44	53	Activated	T052	C1879547
27960292	54	76	Hepatic Stellate Cells	T025	C2340138
27960292	85	96	Suppression	UnknownType	C0678671
27960292	104	107	Akt	T116,T126	C0164786
27960292	110	115	NF-κB	T116,T129	C0079904
27960292	118	121	p38	T116,T123	C1451465
27960292	122	139	Signaling Pathway	T044	C0037080
27960292	144	153	increased	T081	C0205217
27960292	154	167	proliferation	T043	C0596290
27960292	171	180	activated	T052	C1879547
27960292	181	203	hepatic stellate cells	T025	C2340138
27960292	205	209	HSCs	T025	C2340138
27960292	214	229	associated with	T080	C0332281
27960292	230	246	hepatic fibrosis	T047	C0239946
27960292	251	260	excessive	T080	C0442802
27960292	261	281	extracellular matrix	T024	C0015350
27960292	283	286	ECM	T024	C0015350
27960292	289	296	protein	T116,T123	C0033684
27960292	325	335	inhibitory	T052	C3463820
27960292	336	346	effects of	T080	C1704420
27960292	351	369	Monascus purpureus	T004	C0997449
27960292	381	392	metabolites	T123	C0870883
27960292	394	404	ankaflavin	T109,T123	C1568221
27960292	409	417	monascin	T109	C1871155
27960292	441	444	Akt	T116,T126	C0164786
27960292	447	469	nuclear factor (NF)-κB	T116,T129	C0079904
27960292	474	510	p38 mitogen-activated protein kinase	T116,T126	C1120843
27960292	512	516	MAPK	T116,T126	C1120843
27960292	518	536	signaling pathways	T044	C0037080
27960292	540	546	HSC-T6	T025	C0682523
27960292	548	584	activated hepatic stellate cell line	T025	C0682523
27960292	587	597	Ankaflavin	T109,T123	C1568221
27960292	602	610	monascin	T109	C1871155
27960292	619	626	induced	T169	C0205263
27960292	627	636	apoptosis	T043	C0162638
27960292	641	654	significantly	T078	C0750502
27960292	655	664	inhibited	T080	C0311403
27960292	665	676	cell growth	T043	C0007595
27960292	678	694	cell viabilities	T043	C0007620
27960292	748	761	control cells	T025	C0007634
27960292	774	783	Apoptosis	T043	C0162638
27960292	788	803	G1 phase arrest	T043	C3178834
27960292	805	813	G1 phase	T079	C0079395
27960292	814	825	percentages	T081	C0439165
27960292	879	892	control cells	T025	C0007634
27960292	917	927	correlated	T080	C1707520
27960292	933	942	increased	T081	C0205217
27960292	943	946	p53	T116,T123	C0080055
27960292	951	954	p21	T116,T123	C0288472
27960292	955	961	levels	T034	C0428479
27960292	966	984	caspase 3 activity	T044	C1150132
27960292	989	998	decreased	T081	C0205216
27960292	999	1008	cyclin D1	T116,T123	C0174680
27960292	1013	1033	Bcl-2-family protein	T026	C3269083
27960292	1034	1040	levels	T034	C0428479
27960292	1068	1077	apoptotic	T080	C1516044
27960292	1078	1088	effects of	T080	C1704420
27960292	1089	1099	ankaflavin	T109,T123	C1568221
27960292	1104	1112	monascin	T109	C1871155
27960292	1118	1124	HSC-T6	T025	C0682523
27960292	1127	1135	specific	T080	C0205369
27960292	1154	1163	potential	T080	C3245505
27960292	1167	1175	treating	T169	C1522326
27960292	1176	1190	liver fibrosis	T047	C0239946